Profile
Sector:
HealthcareCountry:
IrelandIPO:
16 July 1991Website:
http://www.alkermes.comNext earnings report:
26 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
ALKS Latest News
DUBLIN , May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Jefferies Healthcare Conference Date/Time: Thursday, June 6, 2024 at 1:30 p.m.
– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations – – Findings From In-Depth Qualitative Patient Interviews on the Burden of Narcolepsy Will Also Be Presented – DUBLIN , May 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.
As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resurgence.
Alkermes (ALKS) falls short of first-quarter 2024 earnings and revenue expectations, but sees an increase in revenue compared to the previous year due to strong sales of its proprietary products.
The key figures for Alkermes (ALKS) offer a glimpse into the company's performance in the first quarter of 2024, but it could be beneficial to compare certain metrics to analyst forecasts and the previous year's results.
Alkermes (ALKS) reported quarterly earnings of $0.44 per share, falling short of the Zacks Consensus Estimate of $0.59 per share. This is an improvement from earnings of $0.01 per share in the same quarter last year.
Alkermes (ALKS) announces encouraging results from a phase Ib study evaluating ALKS 2680 as a potential treatment for narcolepsy.
Alkermes announces promising Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, demonstrating strong effectiveness and tolerable side effects. The company intends to move forward with a Phase 2 trial for ALKS-2680 in Narcolepsy Type 2 in the near future. Q4 earnings reveal impressive revenue growth, with Lybalvi leading the way with a 61% increase compared to other products.
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What type of business is Alkermes?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
What sector is Alkermes in?
Alkermes is in the Healthcare sector
What industry is Alkermes in?
Alkermes is in the Drug Manufacturers - Specialty & Generic industry
What country is Alkermes from?
Alkermes is headquartered in Ireland
When did Alkermes go public?
Alkermes initial public offering (IPO) was on 16 July 1991
What is Alkermes website?
https://www.alkermes.com
Is Alkermes in the S&P 500?
No, Alkermes is not included in the S&P 500 index
Is Alkermes in the NASDAQ 100?
No, Alkermes is not included in the NASDAQ 100 index
Is Alkermes in the Dow Jones?
No, Alkermes is not included in the Dow Jones index
When does Alkermes report earnings?
The next expected earnings date for Alkermes is 26 July 2024